Fresenius Kabi and Mayo Clinic Enter into Multiyear Supply and Service Agreement for the Ivenix® Infusion System

December 14, 2023

Fresenius Kabi announced today it has signed a multiyear agreement under which the Mayo Clinic is expected to purchase 10,000 Ivenix® large-volume infusion pumps for its hospitals and clinics in Minnesota, Arizona and Florida.

Infusion pumps are used throughout hospitals and other sites of care to deliver medications and fluids to patients. The Fresenius Kabi Ivenix® Infusion System is a uniquely designed advanced-technology smart pump with a smartphone-like touchscreen and patented pumping mechanism. Ivenix® pumps also interface with hospital information systems and electronic medical records.

“Technology is transforming patient care, and at Fresenius Kabi our focus is on scaling advanced technologies and essential medicines so they can benefit more patients in more places,” said Dr. Christian Hauer, President, Fresenius Kabi MedTech. “We are honored to collaborate with – and to serve – the care teams at Mayo."  

This is the largest contract for Ivenix® pumps Fresenius Kabi has signed to date. 

“For our customers, patients and partners, Fresenius Kabi is committed to enhancing the intelligence and reliability of infusion systems,” said Pete Allen, Senior Vice President, U.S. Infusion Therapy and Nutrition. “This agreement represents the culmination of a tremendous amount of work by our engineering and commercialization teams, and we are committed to delivering an outstanding experience for Mayo and its care teams.”


About Fresenius Kabi:

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition. The company’s products and services are used for the therapy and care of critically and chronically ill patients. 

Its product portfolio comprises a range of highly complex biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs. Within biopharmaceuticals, Fresenius Kabi offers, among others, biosimilar drugs with a focus on autoimmune diseases and oncology. The company’s clinical nutrition offering includes a wide selection of enteral and parenteral nutrition products. In the segment of medical technologies, its offering includes vital disposables, infusions pumps, apheresis machines, cell therapy devices, and more. 

With its corporate mission of "caring for life", Fresenius Kabi puts essential medicines and technologies in the hands of people who help patients and finds the best answers to the challenges they face. 

Following its “Vision 2026”, the company is furthermore committed to increase efficiencies in the therapy and care of patients and improve access to high-quality healthcare around the globe. Fresenius Kabi aspires to be leading globally in its product segments – all for the benefit of patients, its customers, and its stakeholders.

For more information, please visit www.fresenius-kabi.com.



Related News